Prue E. Allan

Melbourne, VIC, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 14 publications

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.

Assessment of candidate high-grade serous ovarian carcinoma predisposition genes through integrated germline and tumour sequencing.

Journal: NPJ genomic medicine

Published: April 22, 2024

Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.

Mucinous ovarian carcinoma: A survey of practice in Australia and New Zealand.

Journal: The Australian & New Zealand journal of obstetrics & gynaecology

Published: July 20, 2023

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.

Estrogen receptor beta expression in triple negative breast cancers is not associated with recurrence or survival.

Journal: BMC cancer

Published: January 16, 2023

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours.

Molecular comparison of pure ovarian fibroma with serous benign ovarian tumours.

Journal: BMC research notes

Published: June 01, 2020

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

Refined cut-off for TP53 immunohistochemistry improves prediction of TP53 mutation status in ovarian mucinous tumors: implications for outcome analyses.

Journal: Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc

Published: May 13, 2020

Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.

Genomic analysis of low-grade serous ovarian carcinoma to identify key drivers and therapeutic vulnerabilities.

Journal: The Journal of pathology

Published: March 03, 2020

Therapeutic options for mucinous ovarian carcinoma.

Therapeutic options for mucinous ovarian carcinoma.

Journal: Gynecologic oncology

Published: October 09, 2019

The molecular origin and taxonomy of mucinous ovarian carcinoma.

The molecular origin and taxonomy of mucinous ovarian carcinoma.

Journal: Nature communications

Published: December 11, 2018

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: June 08, 2017

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Erratum to: Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Journal: Genome medicine

Published: December 15, 2016

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Molecular profiling of low grade serous ovarian tumours identifies novel candidate driver genes.

Journal: Oncotarget

Published: August 14, 2015

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Mutational landscape of mucinous ovarian carcinoma and its neoplastic precursors.

Journal: Genome medicine

Published: June 02, 2015

Showing 1-12 of 14

Last Updated: 09/26/2026